Comparaison du devenir après radiothérapie ablative stéréotaxique des patients souffrant d’une tumeur pulmonaire primitive versus une tumeur métachrone
Year: 2021
Type: dissertation
Study design: Observational Study
Abstract: Introduction: early-stage lung cancer, whose management relies on parenchymal resection surgery, is in nearly a quarter of cases not operable (impaired respiratory function , prior thoracic surgery, severe comorbidities). Stereotactic ablative radiotherapy (SABR) is a non-surgical alternative that provides radical local treatment. This technique, particularly relevant in resectable but nonoperable tumors, is poorly evaluated in metachronous lung tumors. Objective: the objective of this study is to evaluate the clinical outcome of patients treated with SABR for metachronous lung tumor versus primary stage I lung tumor. Material and methods: 137 patients treated with SABR for stage I non-small cell lung carcinoma were retrospectively included, of whom 28/137 were treated for stage I metachronous tumor and 109/137 for stage I primary lung tumor. Clinical follow-up, overall survival, recurrence-free survival, metastasis-free survival, tumor control, toxicities, and dosimetry were collected. Results: after SABR, patients treated for metachronous lung tumor have survival comparable to that of patients treated for stage I primary lung tumor, with no significant increase in the rate of severe toxicities. SABR is a relevant approach to treat localized metachronous lung tumors, especially in unoperable patients.
Source: HAL
Author: Benzaquen, Jonathan
Institution: Université Côte d'Azur
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W7064636849